Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P000025/S137

MED-EL Cochlear Implant

Med-El Corp. · Decision date Jan 23, 2026

FDA DECISIONP000025/S137

What did the FDA approve?

FDA records P000025/S137 as a supplement to PMA P000025, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jan 23, 2026.

FDA approval order statement

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement, which requested approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P000025/S134 Based upon the information submitted, the PMA supplement is approved.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Ear, Nose, Throat
Decision date
Jan 23, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P000025/S137
Regulatory pathway
PMA supplement
Applicant
Med-El Corp.
Product code
MCM
Decision code
APPR
Decision date
Jan 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, cochlear.

Applicant
Med-El Corp.
Product code
MCM
FDA device class
3

For the original device and its historical approval scope, see PMA P000025. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P000025 · Original PMA

    COMBI 40+ COCHLEAR IMPLANT SYSTEM

  2. P000025/S137 received

    Application receipt date recorded by FDA.

  3. P000025/S137 · FDA decision

    Normal 180 Day Track No User Fee

  4. P000025/S136 · Related supplement

    MED-EL Cochlear Implant System

Timeline entries are records held by MedtechLedger for P000025. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P000025

Product / regulatory recordCompanyPathwayDecision dateSource
Med-El Corp.PMA approvalAug 20, 2001FDA
MED-EL CI SystemP000025/S134
Med-El Corp.PMA supplementNov 26, 2025FDA
Med-El Corp.PMA supplementOct 9, 2026FDA

Explore the linked device profile

Other records with product code MCM

Product / regulatory recordCompanyPathwayDecision dateSource
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Advanced BionicsPMA supplementSep 18, 2026FDA
Advanced BionicsPMA supplementSep 4, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Med-El Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Furstenweg 77a, Innsbruck, 6020

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records